💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoquine in babesiosis (Oct 2025)• First patient cured of relapsing babesiosis using tafenoquine-based regimen• Three clinical trials underway, with data expected in 2026 to support a supplementary NDA• $245M peak U.S. market potential and ~$1.1B cumulative revenue opportunity through 2035• Commercial launch underway for ARAKODA® in malaria prevention as travel rebounds📈 Why This Matters for Investors:60 Degrees Pharmaceuticals is one of the smallest Nasdaq-listed biotechs with an FDA-approved product — and it’s pursuing a capital-efficient expansion into a large, underserved infectious disease market. With strong early efficacy signals, a clear regulatory roadmap, and increasing awareness of babesiosis nationwide, SXTP offers investors exposure to a high-upside, low-cost clinical advancement story.🧬 About the Company:60 Degrees Pharmaceuticals (Nasdaq: SXTP) develops and commercializes therapeutics for vector-borne diseases. Its lead product, ARAKODA®, is FDA-approved for malaria prevention and is being advanced into new indications including babesiosis.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!60 Degrees Pharmaceuticals is a client of RedChip. To learn more about SXTP and to read our full disclosure, visit: SXTPinfo.com.#SXTP #BiotechStocks #FDAApproval #PharmaInvesting #MicroCapStocks #InfectiousDiseases #Babesiosis #MalariaPrevention #HealthcareInnovation #Investors